Ikapharmindo Putramas Tbk.

What makes up the 27

MeasureValueBeats peers

• Value

  33Against 788 other IDX companies

  Expensive against comparable stocks.

  P/E

  Loss

  13%Cheaper than 13% of other IDX companies

  P/B

  1.09×

  53%Cheaper than 53% of other IDX companies

  Dividend yield

  —

  —Not ranked

• Quality

  16Against 788 other IDX companies

  Less profitable than most comparable stocks.

  Return on equity

  -7.6%

  14%Higher than 14% of other IDX companies

  Return on assets

  -3.6%

  15%Higher than 15% of other IDX companies

  Net margin

  -4.2%

  20%Higher than 20% of other IDX companies

• Growth

  70Against 788 other IDX companies

  Growing faster than most comparable stocks.

  Profit, last 4 quarters

  —

  —Not ranked

  Profit, 3-year yearly

  —

  —Not ranked

  Profit, latest quarter vs a year ago

  —

  —Not ranked

  Revenue, latest quarter vs a year ago

  +27.2%

  70%Higher than 70% of other IDX companies

• Momentum

  25Against 836 traded stocks

  Has lagged most stocks over the past year.

  1-year price change

  -38.9%

  25%Better than 25% of traded stocks

• Liquidity

  8Against 836 traded stocks

  Thinly traded compared with most IDX stocks.

  Value traded per day, 30 days

  IDR 37M

  8%Higher than 8% of traded stocks

• Retail penalty

  −3Retail brokers XL, XC, RO, YP, past 20 sessions

  Retail is underwater here, deeper than 62% of the other stocks where it is, so 3 points come off the rating.

  Retail average buy

  176

  Close vs that average

  -18.9%

  Retail net bought

  -186 lots

Ownership changes

Changes reported in IDX ownership filings, including directors and major shareholders. Unchanged daily snapshots and extractions below 70% confidence are omitted.

See who is buying IKPM right now

Broker flow, running trades and orderbook depth for every IDX stock, with screeners and backtests on top.

Recent IDX disclosures

Filings published on IDX in the last two years, newest first. Titles are as filed.

How this page is built